BioXcel Therapeutics Files for Bankruptcy Just Weeks Before Key FDA Decision
Biotech company BioXcel Therapeutics (BTAI) filed for Chapter 11 bankruptcy on August 27, just 11 weeks before the U.S. Food and Drug Administration is expected to rule on an expanded label approval for its only approved product, Igalmi. The drug was initially approved in April 2022 but has struggled commercially, with annual revenue never exceeding $2.3 million and plummeting to just $600,000 in 2025 amid a widening net loss of $69.9 million. Despite multiple amendments—14 total—to its financing agreement since November 2023, the company could not meet financial obligations as debt terms became more restrictive. Teva Pharmaceuticals (TEVA) has emerged as a stalking horse bidder for BioXcel’s assets with an offer of $57.5 million in cash at closing and up to $67.5 million contingent on regulatory approval milestones, highlighting the market's focus on potential post-FDA value despite current financial distress.
Topics: Biotech Chapter 11 Filing FDA Approval Investing Risks